<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6551">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007435</url>
  </required_header>
  <id_info>
    <org_study_id>WA19926</org_study_id>
    <secondary_id>2009-012759-12</secondary_id>
    <nct_id>NCT01007435</nct_id>
  </id_info>
  <brief_title>A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, parallel group study will assess the safety, disease
      remission, and prevention of structural joint damage in patients with early moderate to
      severe rheumatoid arthritis treated with tocilizumab as monotherapy or in combination with
      methotrexate, versus methotrexate alone. Patients will be randomized to receive either (A)
      tocilizumab (8 mg/kg iv every 4 weeks) plus placebo, (B) tocilizumab (8 mg/kg iv every 4
      weeks) plus methotrexate (7.5-20 mg po weekly), (C) tocilizumab (4 mg/kg iv every 4 weeks)
      plus methotrexate (7.5-20 mg po weekly), or (D) placebo plus methotrexate (7.5-20 mg po
      weekly). Patients in groups C and D who have not achieved low disease activity at week 52
      can receive tocilizumab 8 mg/kg iv every 4 weeks. Anticipated time on study treatment is 104
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A participant has a DAS28 remission response if their DAS28 &lt; 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52</measure>
    <time_frame>Baseline to Weeks 24 and 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line &quot;no disease activity&quot; [symptom-free and no arthritis symptoms] and the extreme right end &quot;maximum disease activity&quot;; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line &quot;no pain&quot; and the extreme right end &quot;unbearable pain&quot;); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Sharp Erosion Score at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sharp Joint Space Narrowing Score at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Clinical Response at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52</measure>
    <time_frame>Baseline to Weeks 24 and 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52</measure>
    <time_frame>Baseline to Weeks 24 and 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1162</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>(A) Tocilizumab 8 mg/kg + placebo to methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(B) Tocilizumab 8 mg/kg + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(C) Tocilizumab 4 mg/kg + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(D) Placebo to tocilizumab + methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab was supplied in vials.</description>
    <arm_group_label>(A) Tocilizumab 8 mg/kg + placebo to methotrexate</arm_group_label>
    <arm_group_label>(B) Tocilizumab 8 mg/kg + methotrexate</arm_group_label>
    <arm_group_label>(C) Tocilizumab 4 mg/kg + methotrexate</arm_group_label>
    <other_name>RoActemra</other_name>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to tocilizumab</intervention_name>
    <description>Placebo to tocilizumab was supplied in vials.</description>
    <arm_group_label>(D) Placebo to tocilizumab + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.</description>
    <arm_group_label>(B) Tocilizumab 8 mg/kg + methotrexate</arm_group_label>
    <arm_group_label>(C) Tocilizumab 4 mg/kg + methotrexate</arm_group_label>
    <arm_group_label>(D) Placebo to tocilizumab + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to methotrexate</intervention_name>
    <description>Patients received placebo to methotrexate orally once a week.</description>
    <arm_group_label>(A) Tocilizumab 8 mg/kg + placebo to methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients ≥ 18 years of age.

          -  Rheumatoid arthritis of ≤ 2 years duration.

          -  Disease Activity Score 28 (DAS28) &gt; 3.2.

          -  Swollen joint count (SJC) ≥ 4 of 66 joints, tender joint count (TJC) ≥ 6 of 68
             joints.

          -  Rheumatoid factor (RF) and/or anti−cyclic citrullinated peptide (anti-CCP) positive
             (if RF and anti-CCP negative &gt; 1 erosion required at screening).

          -  Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h or C-reactive protein (CRP) ≥ 10 mg/L
             at screening.

        Exclusion Criteria:

          -  Previous treatment with tocilizumab.

          -  Previous treatment with methotrexate or biologic agent.

          -  Rheumatic autoimmune disease other than rheumatoid arthritis (RA).

          -  History of or current inflammatory joint disease other than RA.

          -  Functional class IV as defined by the American College of Rheumatology (ACR)
             Classification of Functional Status in RA.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Passaic</city>
        <state>New Jersey</state>
        <zip>07055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801-0489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428DQG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hobart</city>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maroochydore</city>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <zip>13060-803</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <zip>74653-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Juiz de Fora</city>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04037-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 5N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2N 7E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trois-rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellin-antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellin</city>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyvinkää</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orleans</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baden-baden</city>
        <zip>76530</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <zip>01013</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>78306</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magenta</city>
        <zip>20013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monserrato</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Culiacan</city>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saltillo</city>
        <zip>25000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torreon</city>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <zip>2100</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timaru</city>
        <zip>7910</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <zip>32400</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>LIMA 14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>Lima 21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>LIMA 29</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manila</city>
        <zip>1015</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bytom</city>
        <zip>41902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <zip>410002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <zip>97500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian de Los Reyes</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cannock</city>
        <zip>WS11 5XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Derby</city>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M41 5SL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stoke-on-trent</city>
        <zip>ST6 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wirral</city>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worthing</city>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>November 3, 2009</firstreceived_date>
  <firstreceived_results_date>May 23, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Five of 1162 randomized patients (2 placebo to tocilizumab + methotrexate, 2 tocilizumab 4 mg/kg + methotrexate, 1 tocilizumab 8 mg/kg + methotrexate) did not receive any study treatment and were excluded from all analysis populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo to Tocilizumab + Methotrexate</title>
          <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tocilizumab 4 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Tocilizumab 8 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="291"/>
                <participants group_id="P4" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="227"/>
                <participants group_id="P4" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Selection Criteria at Entry</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics were based on the intent-to-treat (ITT) population. Five of 1162 randomized patients (2 placebo + methotrexate, 2 tocilizumab 4 mg/kg + methotrexate, 1 tocilizumab 8 mg/kg + methotrexate) did not receive any study treatment and were excluded from all analysis populations. The ITT population therefore included 1157 patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo to Tocilizumab + Methotrexate</title>
          <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Tocilizumab 4 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Tocilizumab 8 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="287"/>
                <measurement group_id="B2" value="288"/>
                <measurement group_id="B3" value="290"/>
                <measurement group_id="B4" value="292"/>
                <measurement group_id="B5" value="1157"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49.6" spread="13.10"/>
                <measurement group_id="B2" value="51.2" spread="13.84"/>
                <measurement group_id="B3" value="49.5" spread="13.70"/>
                <measurement group_id="B4" value="49.9" spread="13.22"/>
                <measurement group_id="B5" value="50.1" spread="13.47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="229"/>
                <measurement group_id="B2" value="228"/>
                <measurement group_id="B3" value="228"/>
                <measurement group_id="B4" value="219"/>
                <measurement group_id="B5" value="904"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="62"/>
                <measurement group_id="B4" value="73"/>
                <measurement group_id="B5" value="253"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24</title>
        <description>A participant has a DAS28 remission response if their DAS28 &lt; 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient’s global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.</description>
        <time_frame>Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="287"/>
                  <measurement group_id="O2" value="288"/>
                  <measurement group_id="O3" value="290"/>
                  <measurement group_id="O4" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24</title>
            <description>A participant has a DAS28 remission response if their DAS28 &lt; 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient’s global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15.0" lower_limit="10.9" upper_limit="19.1"/>
                  <measurement group_id="O2" value="31.9" lower_limit="26.6" upper_limit="37.3"/>
                  <measurement group_id="O3" value="44.8" lower_limit="39.1" upper_limit="50.6"/>
                  <measurement group_id="O4" value="38.7" lower_limit="33.1" upper_limit="44.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the DAS28 remission response at Week 24 between the placebo to tocilizumab + methotrexate and the tocilizumab 8 mg/kg + methotrexate treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The stratification factors, region and serologic status, were included in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.19</ci_lower_limit>
            <ci_upper_limit>7.14</ci_upper_limit>
            <estimate_desc>Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to “non-responder”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the DAS28 remission response at Week 24 between the placebo to tocilizumab + methotrexate and the tocilizumab 8 mg/kg + placebo to methotrexate treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The stratification factors, region and serologic status, were included in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.47</ci_lower_limit>
            <ci_upper_limit>5.55</ci_upper_limit>
            <estimate_desc>Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to “non-responder”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the DAS28 remission response at Week 24 between the placebo to tocilizumab + methotrexate and the tocilizumab 4 mg/kg + methotrexate treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons. This comparison came after the break in statistical hierarchy.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The stratification factors, region and serologic status, were included in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
            <estimate_desc>Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to “non-responder”.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52</title>
        <time_frame>Week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="287"/>
                  <measurement group_id="O2" value="288"/>
                  <measurement group_id="O3" value="290"/>
                  <measurement group_id="O4" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19.5"/>
                  <measurement group_id="O2" value="34.0"/>
                  <measurement group_id="O3" value="49.0"/>
                  <measurement group_id="O4" value="39.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52</title>
        <description>Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line “no disease activity” [symptom-free and no arthritis symptoms] and the extreme right end “maximum disease activity”; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line “no pain” and the extreme right end “unbearable pain”); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.</description>
        <time_frame>Baseline to Weeks 24 and 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="287"/>
                  <measurement group_id="O2" value="288"/>
                  <measurement group_id="O3" value="290"/>
                  <measurement group_id="O4" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52</title>
            <description>Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line “no disease activity” [symptom-free and no arthritis symptoms] and the extreme right end “maximum disease activity”; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line “no pain” and the extreme right end “unbearable pain”); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Week 24: ACR 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.2"/>
                  <measurement group_id="O2" value="73.6"/>
                  <measurement group_id="O3" value="74.5"/>
                  <measurement group_id="O4" value="70.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24: ACR 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.2"/>
                  <measurement group_id="O2" value="47.9"/>
                  <measurement group_id="O3" value="56.9"/>
                  <measurement group_id="O4" value="47.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24: ACR 70</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.4"/>
                  <measurement group_id="O2" value="34.7"/>
                  <measurement group_id="O3" value="38.6"/>
                  <measurement group_id="O4" value="30.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52: ACR 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57.1"/>
                  <measurement group_id="O2" value="62.8"/>
                  <measurement group_id="O3" value="67.2"/>
                  <measurement group_id="O4" value="63.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52: ACR 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40.8"/>
                  <measurement group_id="O2" value="52.4"/>
                  <measurement group_id="O3" value="55.9"/>
                  <measurement group_id="O4" value="49.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52: ACR 70</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.9"/>
                  <measurement group_id="O2" value="37.2"/>
                  <measurement group_id="O3" value="43.1"/>
                  <measurement group_id="O4" value="36.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</title>
        <description>The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="267"/>
                  <measurement group_id="O2" value="267"/>
                  <measurement group_id="O3" value="273"/>
                  <measurement group_id="O4" value="275"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</title>
            <description>The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" spread="4.297"/>
                  <measurement group_id="O2" value="0.42" spread="2.929"/>
                  <measurement group_id="O3" value="0.08" spread="2.090"/>
                  <measurement group_id="O4" value="0.26" spread="1.876"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Sharp Erosion Score at Week 52</title>
        <time_frame>Baseline to Week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="267"/>
                  <measurement group_id="O2" value="267"/>
                  <measurement group_id="O3" value="273"/>
                  <measurement group_id="O4" value="275"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Modified Sharp Erosion Score at Week 52</title>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.63" spread="2.556"/>
                  <measurement group_id="O2" value="0.25" spread="1.686"/>
                  <measurement group_id="O3" value="0.05" spread="1.736"/>
                  <measurement group_id="O4" value="0.15" spread="1.544"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sharp Joint Space Narrowing Score at Week 52</title>
        <time_frame>Baseline to Week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="267"/>
                  <measurement group_id="O2" value="268"/>
                  <measurement group_id="O3" value="273"/>
                  <measurement group_id="O4" value="275"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Sharp Joint Space Narrowing Score at Week 52</title>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.51" spread="2.362"/>
                  <measurement group_id="O2" value="0.17" spread="1.645"/>
                  <measurement group_id="O3" value="0.03" spread="0.751"/>
                  <measurement group_id="O4" value="0.11" spread="1.046"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Clinical Response at Week 52</title>
        <description>A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="287"/>
                  <measurement group_id="O2" value="288"/>
                  <measurement group_id="O3" value="290"/>
                  <measurement group_id="O4" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With a Major Clinical Response at Week 52</title>
            <description>A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52</title>
        <description>The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.</description>
        <time_frame>Baseline to Weeks 24 and 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="287"/>
                  <measurement group_id="O2" value="288"/>
                  <measurement group_id="O3" value="290"/>
                  <measurement group_id="O4" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52</title>
            <description>The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 24 (n=246, 255, 250, 265)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.71" spread="0.718"/>
                  <measurement group_id="O2" value="-0.92" spread="0.736"/>
                  <measurement group_id="O3" value="-0.91" spread="0.695"/>
                  <measurement group_id="O4" value="-0.82" spread="0.739"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52 (n=214, 227, 228, 230)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.76" spread="0.800"/>
                  <measurement group_id="O2" value="-1.00" spread="0.795"/>
                  <measurement group_id="O3" value="-0.97" spread="0.700"/>
                  <measurement group_id="O4" value="-0.87" spread="0.776"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52</title>
        <description>The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.</description>
        <time_frame>Baseline to Weeks 24 and 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="287"/>
                  <measurement group_id="O2" value="288"/>
                  <measurement group_id="O3" value="290"/>
                  <measurement group_id="O4" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52</title>
            <description>The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 24 (n=237, 247, 246, 255)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.35" spread="9.763"/>
                  <measurement group_id="O2" value="11.33" spread="9.282"/>
                  <measurement group_id="O3" value="12.13" spread="9.263"/>
                  <measurement group_id="O4" value="10.75" spread="10.055"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 52 (n=204, 225, 221, 224)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.72" spread="10.389"/>
                  <measurement group_id="O2" value="12.27" spread="10.509"/>
                  <measurement group_id="O3" value="13.52" spread="9.848"/>
                  <measurement group_id="O4" value="11.73" spread="10.691"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from Baseline through Week 52.</time_frame>
      <desc>Safety population: All patients who received at least 1 tocilizumab/placebo infusion and had at least 1 post-dose safety assessment. 7 patients were excluded from the safety population (no treatment received or no post-baseline safety data). The total safety population included 1153 patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo to Tocilizumab + Methotrexate</title>
          <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Tocilizumab 4 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Tocilizumab 8 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Neurosensory hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Oteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Endometrial cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Renal cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="201" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="163" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
